Results of additional issuance - RIKB 28 1115
As stated in paragraph 6 in General Terms of Auction for Treasury bonds, the Government Debt Management offered the equivalent of 10% of the nominal value sold in the auction 26. May, at the price of accepted bids.
| Series | RIKB 28 1115 |
| ISIN | IS0000028249 |
| Additional issuance (nominal) | 29,000,000 |
| Settlement date | 05/31/2023 |
| Total outstanding (nominal) | 103,350,801,519 |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)25.9.2023 11:55:00 CEST | Press release
Media Release Subcutaneous EPKINLYTM(epcoritamab) is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapyApproval based on results of EPCORETM NHL-3 and EPCORETM NHL-1 clinical trials, evaluating EPKINLYin patients with certain types of R/RLBCLLBCLis a common form of non-Hodgkin’s lymphoma (NHL) and currently has limited treatment options, particularly in the R/R setting COPENHAGEN, Denmark; September 25, 2023 – Genmab A/S (Nasdaq:GMAB) announcedtoday that the Japan Ministry of Health, Labour and Welfare has approved EPKINLYTM (epcoritamab) as the first and only T-cell engaging bispecific antibody treatment in Japan of adult patients with certain types of relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL)
Wolters Kluwer identifies ESG reporting challenges, demonstrates how technology brings clarity and competitive advantage25.9.2023 11:01:56 CEST | Press release
PRESS RELEASE Wolters Kluweridentifies ESG reporting challenges,demonstrates howtechnology brings clarity and competitive advantage Wolters Kluwer’s Corporate Performance and ESG divisionpoised to play leading role in enabling businesses to navigate emerging ESG reporting challenges LONDON – September 25, 2023– Wolters Kluwer’s Corporate Performance & ESG (CP & ESG) division has set out key issues major corporate and financial services institutions should consider when tackling emerging ESG reporting challenges. The insights are featured in a new white paper, “Bringing clarity to the complexity of financial and ESG reporting,” which zeroes in on the significant impact that the expected enforcement of global ESG regulations will have on multinational companies. The paper, authored by Wolters Kluwer CP & ESG experts, recommends that companies work quickly to leverage technology to bring clarity to the myriad of ESG expectations they face, by transforming the way they collect, report, ana
International Petroleum Corporation Announces Results of Normal Course Issuer Bid25.9.2023 11:00:00 CEST | Press release
International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO)is pleased to announce that IPC repurchased a total of254,700IPC common shares (ISIN: CA46016U1084) during the period of September 18 to 22, 2023under IPC’s normal course issuer bid / share repurchase program (NCIB). IPC’s NCIB, announced on December 1, 2022, is being implemented in accordance with the Market Abuse Regulation (EU) No 596/2014 (MAR) and Commission Delegated Regulation (EU) No 2016/1052 (Safe Harbour Regulation) and the applicable rules and policies of the Toronto Stock Exchange (TSX) and Nasdaq Stockholm and applicable Canadian and Swedish securities laws. During the period of September 18 to 22, 2023, IPC repurchased a total of 210,000 IPC common shares on Nasdaq Stockholm. All of these share repurchases were carried out by Pareto Securities AB on behalf of IPC. For more information regarding transactions under the NCIB in Sweden, including aggregated volume, weighted average pric
Festi hf.: Buyback program week 3825.9.2023 11:00:00 CEST | Press release
In week 38 2023, Festi purchased in total 130,000 own shares for total amount of 23,320,000 ISK as follows: WeekDateTimePurchased sharesShare pricePurchase price 38 19.sep 14:16:19 70.000 179,5 12.565.000 38 20.sep 13:55:36 30.000 179,5 5.385.000 38 21.sep 11:08:26 15.000 179 2.685.000 38 21.sep 14:53:42 15.000 179 2.685.000 130.00023.320.000 The execution of the buyback program is in accordance with the Act on Public Limited Companies No 2/1995, Article 5 of the Regulation of the European parliament and of the Council No. 596/2014, on market abuse, the Commissions Delegated Regulation No. 2016/1052 and the Act on Actions against Market Fraud No. 60/2021. Before the purchase Festi held 9,275,668 own shares or 2.97% of issued shares. Festi has now bought in total 1,405,668 own shares for 265,982,037 ISK and holds today 9,405,668 own shares or 3.01% of issued shares. This announcement of purchase of own shares is in accordance with the buyback program announced 21 July 2023 to Nasdaq OMX
Share buy-back programme - week 3825.9.2023 10:30:44 CEST | Press release
Nasdaq Copenhagen London Stock Exchange Euronext Dublin Other stakeholders Date 25.09.2023 Share buy-back programme - week 38 The share buy-back programme runs from and including 3 August 2023 up to and including 22 January 2024. During this period Ringkjøbing Landbobank will buy-back shares to a maximum market value of DKK 385 million under a share buy-back programme, see company announcement of 2 August 2023. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been made under the programme: DateNumber of sharesAverage purchase price (DKK)Total purchased under the programme (DKK)Total in accordance with the last announcement120,7001,010.12121,921,00318 September 20235,000989.804,949,00019 September 20234,500986.254,438,12520 September 20232,6001,004.722,612,27221 September 20234